News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
818,925 Results
Type
Article (74619)
Company Profile (647)
Press Release (743659)
Multimedia
Podcasts (126)
Webinars (14)
Section
Business (227771)
Career Advice (3724)
Deals (39351)
Drug Delivery (129)
Drug Development (89469)
Employer Resources (198)
FDA (17888)
Job Trends (17157)
News (388311)
Policy (38850)
Tag
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (96)
Alliances (56065)
ALS (104)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (164)
Approvals (17843)
Artificial intelligence (310)
Autoimmune disease (29)
Automation (16)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (440)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (313)
Cancer (2482)
Cardiovascular disease (210)
Career advice (3173)
Career pathing (34)
CAR-T (176)
Cell therapy (492)
Cervical cancer (22)
Clinical research (72365)
Collaboration (935)
Company closure (2)
Compensation (578)
Complete response letters (30)
COVID-19 (2868)
CRISPR (50)
C-suite (275)
Cystic fibrosis (109)
Data (2361)
Decentralized trials (2)
Denatured (43)
Depression (56)
Diabetes (302)
Diagnostics (6924)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (130)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (94350)
Editorial (47)
Employer branding (25)
Employer resources (167)
Events (129158)
Executive appointments (788)
FDA (19317)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (826)
Gene editing (125)
Generative AI (28)
Gene therapy (364)
GLP-1 (860)
Government (5127)
Grass and pollen (6)
Guidances (150)
Healthcare (20874)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (152)
Indications (30)
Infectious disease (3031)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (102)
Interviews (727)
IPO (17765)
IRA (51)
Job creations (5007)
Job search strategy (2596)
Kidney cancer (11)
Labor market (47)
Layoffs (564)
Leadership (24)
Legal (9928)
Liver cancer (82)
Lung cancer (349)
Lymphoma (161)
Machine learning (9)
Management (65)
Manufacturing (365)
MASH (81)
Medical device (14624)
Medtech (14629)
Mergers & acquisitions (22153)
Metabolic disorders (806)
Multiple sclerosis (89)
NASH (23)
Neurodegenerative disease (116)
Neuropsychiatric disorders (34)
Neuroscience (2120)
NextGen: Class of 2025 (7638)
Non-profit (5080)
Now hiring (41)
Obesity (433)
Opinion (275)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (162)
Partnered (22)
Patents (258)
Patient recruitment (119)
Peanut (51)
People (64197)
Pharmaceutical (136)
Pharmacy benefit managers (22)
Phase I (22372)
Phase II (31569)
Phase III (23783)
Pipeline (1397)
Policy (180)
Postmarket research (3262)
Preclinical (9878)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (437)
Real estate (7165)
Recruiting (75)
Regulatory (26166)
Reports (58)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (82)
Series A (144)
Series B (94)
Service/supplier (27)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4203)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (54)
The Weekly (81)
Vaccines (822)
Venture capitalists (45)
Weight loss (306)
Women's health (39)
Worklife (20)
Date
Today (40)
Last 7 days (988)
Last 30 days (3236)
Last 365 days (34983)
2025 (12569)
2024 (37906)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57663)
2019 (51306)
2018 (39087)
2017 (36854)
2016 (37777)
2015 (43761)
2014 (38468)
2013 (34452)
2012 (36348)
2011 (36468)
2010 (35931)
Location
Africa (1195)
Alabama (61)
Alaska (7)
Arizona (250)
Arkansas (14)
Asia (48813)
Australia (8376)
California (6679)
Canada (2107)
China (574)
Colorado (289)
Connecticut (305)
Delaware (167)
Europe (110211)
Florida (977)
Georgia (226)
Hawaii (1)
Idaho (63)
Illinois (624)
India (30)
Indiana (342)
Iowa (12)
Japan (178)
Kansas (112)
Kentucky (28)
Louisiana (15)
Maine (70)
Maryland (992)
Massachusetts (5107)
Michigan (250)
Minnesota (430)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (69)
New Hampshire (69)
New Jersey (1878)
New Mexico (31)
New York (1876)
North Carolina (1142)
North Dakota (9)
Northern California (2877)
Ohio (224)
Oklahoma (15)
Oregon (46)
Pennsylvania (1463)
Puerto Rico (14)
Rhode Island (36)
South America (1569)
South Carolina (26)
South Dakota (1)
Southern California (2482)
Tennessee (108)
Texas (995)
United States (25448)
Utah (199)
Virginia (175)
Washington D.C. (72)
Washington State (612)
West Virginia (3)
Wisconsin (70)
818,925 Results for "sumitomo dainippon pharma co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib
April 14, 2025
·
5 min read
Press Releases
Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting
April 30, 2025
·
7 min read
Business
RevolKa Ltd.: Announcement of Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd.
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. for rare diseases within the contractually agreed time frame.
June 23, 2023
·
3 min read
Genetown
Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress
Sumitomo Pharma America, Inc. (SMPA) today announced the oral presentation of data from the ongoing Phase 1/2 first-in-human study of DSP-5336 in patients with relapsed or refractory acute leukemia at the European Hematology Association (EHA) 2024 Hybrid Congress.
June 14, 2024
·
7 min read
Press Releases
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments
April 28, 2025
·
10 min read
Press Releases
Kairos Pharma Ltd. Provides Letter to Stockholders
April 24, 2025
·
5 min read
Press Releases
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
December 25, 2024
·
1 min read
Press Releases
Foundation Medicine Collaborates with Sumitomo Pharma America to Advance Investigational Treatment for Patients with Acute Leukemia with NPM1 Mutations or KMT2A Rearrangements Using the FoundationOne®Heme Platform
February 19, 2025
·
4 min read
Drug Development
Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting
Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron.
May 7, 2024
·
8 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
1 of 81,893
Next
